Vertex Pharmaceuticals Inc. / MA (VRTX) stock forecast and price target
Price $538.60 · data as of November 13, 2026
12-month price target
Gold marker: average target · white marker: today’s price ($538.60)
Analyst ratings
Earnings and revenue estimates
| Period | EPS estimate | EPS growth | Revenue estimate |
|---|---|---|---|
| Current fiscal year ends December 31, 2026 | $18.14 | −1.4% | $13.3B |
| Next fiscal year ends December 31, 2027 | $19.92 | +9.8% | $14.7B |
| Next quarter ends December 31, 2026 | $4.10 | −18.4% | $3.5B |
| Quarter after ends March 31, 2027 | $4.68 | +4.7% | $3.4B |
Consensus of the analysts covering Vertex Pharmaceuticals Inc. / MA, updated daily. In the last 30 days 4 estimates were raised and 4 lowered.
Our model vs. Wall Street
Analysts see 10.5% upside over 12 months. Our discounted cash flow model with moderate assumptions puts Vertex Pharmaceuticals Inc. / MA’s intrinsic value about 53% below today’s market value, and it scores 2.4 out of 5 on our checks. Price targets follow sentiment; a DCF follows cash. When both point the same way the signal is stronger. Try your own assumptions.
Frequently asked questions
What is the Vertex Pharmaceuticals Inc. / MA stock price target?
The average 12-month target from 28 analysts is $595.36, 10.5% above the current price of $538.60 Targets range from $350.00 to $725.00.
Is Vertex Pharmaceuticals Inc. / MA a buy according to analysts?
The consensus rating is “Buy” (6 strong buy, 20 buy, 5 hold, 1 sell). Ratings are opinions, not guarantees; this is not investment advice.
How much is Vertex Pharmaceuticals Inc. / MA expected to earn?
Analysts expect EPS of $18.14 for the fiscal year ending December 31, 2026 and $19.92 the year after.
Analyst consensus estimates and price targets, updated daily. Forecasts can be wrong; this is information, not investment advice.